NYSE:IQVIqvia Stock Price, Forecast & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IQV stock has increased by 27.0% and is now trading at $159.31.
View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Iqvia.

Iqvia Holdings Inc (NYSE:IQV) issued its quarterly earnings results on Wednesday, July, 22nd. The medical research company reported $1.18 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.06 by $0.12. The medical research company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.41 billion. Iqvia had a net margin of 1.21% and a return on equity of 17.90%. During the same quarter in the prior year, the firm earned $1.53 earnings per share.
View Iqvia's earnings history.

Iqvia issued an update on its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share (EPS) guidance of $6.10-6.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.87. The company issued revenue guidance of $11.0-11.1 billion, compared to the consensus revenue estimate of $10.73 billion.

17 analysts have issued 1 year target prices for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they expect Iqvia's stock price to reach $165.00 in the next year. This suggests a possible upside of 3.6% from the stock's current price.
View analysts' price targets for Iqvia.

Media stories about IQV stock have been trending negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iqvia earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Iqvia.

Iqvia saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 2,880,000 shares, an increase of 19.0% from the January 31st total of 2,420,000 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is presently 2.1 days. Approximately 1.5% of the shares of the stock are sold short.
View Iqvia's Short Interest.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), Syneos Health (SYNH), PRA Health Sciences (PRAH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), Endologix (ELGX), Alibaba Group (BABA), Micron Technology (MU), Paypal (PYPL), Accenture (ACN) and salesforce.com (CRM).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia's stock is owned by many different retail and institutional investors. Top institutional shareholders include Jackson Square Partners LLC (2.05%), Bessemer Group Inc. (0.92%), Sumitomo Mitsui Trust Holdings Inc. (0.67%), Macquarie Group Ltd. (0.53%), Victory Capital Management Inc. (0.45%) and Swiss National Bank (0.40%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer, Ronald E Bruehlman and W Richard Staub.
View institutional ownership trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Macquarie Group Ltd., Strs Ohio, Jennison Associates LLC, Sumitomo Mitsui Trust Holdings Inc., Bank of Nova Scotia, BI Asset Management Fondsmaeglerselskab A S, and Banco Santander S.A.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Michael J Evanisko, and Michael R Mcdonnell.
View insider buying and selling activity for Iqvia.

IQV stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Veracity Capital LLC, Swiss National Bank, Alberta Investment Management Corp, First Trust Advisors LP, Raymond James & Associates, Raymond James Financial Services Advisors Inc., and Envestnet Asset Management Inc..
View insider buying and selling activity for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $159.31.

Iqvia has a market capitalization of $30.47 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

The official website for Iqvia is www.iqvia.com.

Iqvia's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]